Academic Journal
Allergen immunotherapy for birch pollen-allergic patients: recent advances.
| Title: | Allergen immunotherapy for birch pollen-allergic patients: recent advances. |
|---|---|
| Authors: | Moingeon P; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France., Floch VB; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France., Airouche S; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France., Baron-Bodo V; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France., Nony E; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France., Mascarell L; Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France. |
| Source: | Immunotherapy [Immunotherapy] 2016 May; Vol. 8 (5), pp. 555-67. |
| Publication Type: | Comparative Study; Journal Article; Review; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Future Medicine |
| MeSH Terms: | Antigens, Plant/*therapeutic use , Betula/*immunology , Conjunctivitis, Allergic/*therapy , Desensitization, Immunologic/*methods , Recombinant Proteins/*therapeutic use , Rhinitis, Allergic/*therapy , Rhinitis, Allergic, Seasonal/*therapy, Animals ; Antigens, Plant/immunology ; Clinical Trials as Topic ; Conjunctivitis, Allergic/immunology ; Desensitization, Immunologic/trends ; Humans ; Plant Extracts/therapeutic use ; Pollen/immunology ; Rhinitis, Allergic/immunology ; Rhinitis, Allergic, Seasonal/immunology |
| Abstract: | As of today, allergen immunotherapy is performed with aqueous natural allergen extracts. Recombinant allergen vaccines are not yet commercially available, although they could provide patients with well-defined and highly consistent drug substances. As Bet v 1 is the major allergen involved in birch pollen allergy, with more than 95% of patients sensitized to this allergen, pharmaceutical-grade recombinant Bet v 1-based vaccines were produced and clinically tested. Herein, we compare the clinical results and modes of action of treatments based on either a birch pollen extract or recombinant Bet v 1 expressed as hypoallergenic or natural-like molecules. We also discuss the future of allergen immunotherapy with improved drugs intended for birch pollen-allergic patients suffering from rhinoconjunctivitis. |
| Contributed Indexing: | Keywords: birch pollen; immunotherapy; recombinant Bet v 1 |
| Substance Nomenclature: | 0 (Antigens, Plant) 0 (Plant Extracts) 0 (Recombinant Proteins) 126161-14-6 (Bet v 1 allergen, Betula) |
| Entry Date(s): | Date Created: 20160504 Date Completed: 20170626 Latest Revision: 20171104 |
| Update Code: | 20221216 |
| DOI: | 10.2217/imt-2015-0027 |
| PMID: | 27140409 |
| Database: | MEDLINE |
| ISSN: | 1750-7448 |
|---|---|
| DOI: | 10.2217/imt-2015-0027 |